Gilead Sees Prospects For Declining HCV Revenues To Stabilize
Executive Summary
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.
You may also be interested in...
Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017
A 22% decline in hepatitis C sales year-over-year was offset somewhat by a 17% uptick for the HIV franchise, but the virology powerhouse is guiding for continued HCV falloff in 2017.
Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer
The three most expensive drug categories, on a per-member/per-year basis for the PBM's clients, increased by 19% or more in 2016, and similar growth is expected in the next three years. Per-patient spending on HCV drugs, however, declined by 34% last year.
Which Biopharmas Are Best Positioned For Five-Year Growth?
Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.